PL2032535T3 - Spirocykliczne nitryle jako inhibitory proteazy - Google Patents

Spirocykliczne nitryle jako inhibitory proteazy

Info

Publication number: PL2032535T3
Authority: PL; Poland
Prior art keywords: protease inhibitors; spirocyclic; nitriles; spirocyclic nitriles; protease
Prior art date: 2006-06-01

Application number

PL07725450T

Other languages

English (en)

Inventor

Manfred Schudok

Michael Wagner

Armin Bauer

Anna Kohlmann

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-01

Filing date

2007-05-23

Publication date

2013-01-31

2007-05-23 Application filed by Sanofi Sa filed Critical Sanofi Sa

2013-01-31 Publication of PL2032535T3 publication Critical patent/PL2032535T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Tropical Medicine & Parasitology (AREA)
Dermatology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)

PL07725450T 2006-06-01 2007-05-23 Spirocykliczne nitryle jako inhibitory proteazy PL2032535T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE102006025630		2006-06-01
EP07725450A EP2032535B1 (de)	2006-06-01	2007-05-23	Spiro-cyclische nitrile als protease-inhibitoren
PCT/EP2007/004550 WO2007137738A1 (de)	2006-06-01	2007-05-23	Spiro-cyclische nitrile als protease-inhibitoren

Publications (1)

Publication Number	Publication Date
PL2032535T3 true PL2032535T3 (pl)	2013-01-31

Family

ID=38445013

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07725450T PL2032535T3 (pl)	2006-06-01	2007-05-23	Spirocykliczne nitryle jako inhibitory proteazy

Country Status (38)

Country	Link
US (3)	US8039480B2 (pl)
EP (2)	EP2032535B1 (pl)
JP (2)	JP5312320B2 (pl)
KR (1)	KR101426317B1 (pl)
CN (2)	CN102417480B (pl)
AR (1)	AR061599A1 (pl)
AU (1)	AU2007267470B2 (pl)
BR (1)	BRPI0711723A2 (pl)
CA (1)	CA2653662C (pl)
CR (1)	CR10409A (pl)
CY (1)	CY1113320T1 (pl)
DK (1)	DK2032535T3 (pl)
DO (1)	DOP2007000107A (pl)
EC (1)	ECSP088925A (pl)
ES (1)	ES2392675T3 (pl)
GT (1)	GT200800251A (pl)
HK (2)	HK1133255A1 (pl)
HN (1)	HN2008001723A (pl)
HR (1)	HRP20120852T1 (pl)
IL (1)	IL195519A (pl)
JO (1)	JO2741B1 (pl)
MA (1)	MA30435B1 (pl)
MX (2)	MX2008014800A (pl)
MY (1)	MY156425A (pl)
NO (1)	NO20085107L (pl)
NZ (1)	NZ573049A (pl)
PE (1)	PE20080104A1 (pl)
PL (1)	PL2032535T3 (pl)
PT (1)	PT2032535E (pl)
RS (1)	RS52464B (pl)
RU (2)	RU2478620C2 (pl)
SG (1)	SG172661A1 (pl)
SI (1)	SI2032535T1 (pl)
TN (1)	TNSN08494A1 (pl)
TW (2)	TWI449706B (pl)
UA (2)	UA100669C2 (pl)
WO (1)	WO2007137738A1 (pl)
ZA (1)	ZA200808745B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8389539B2 (en) *	2009-12-01	2013-03-05	Hoffman-La Roche Inc.	Azacyclic derivatives
WO2012047703A2 (en) *	2010-10-04	2012-04-12	Schering Corporation	Cyclopropyl-spiro-piperidines useful as sodium channel blockers
FR2967673B1 (fr)	2010-11-24	2012-12-28	Minakem	Synthese de n-heterocycles par alkylation reductrice de derives cyanes
WO2012119941A1 (en)	2011-03-04	2012-09-13	Prozymex A/S	Peptidyl nitrilcompounds as peptidase inhibitors
CN103304571B (zh) *	2012-03-06	2018-02-16	凯惠科技发展(上海)有限公司	螺环化合物、其制备方法、中间体、药物组合物和应用
RU2016149812A (ru)	2014-06-06	2018-07-17	Флексус Байосайенсиз, Инк.	Иммунорегулирующие средства
CN104250233B (zh) *	2014-08-29	2016-03-16	湖南华腾制药有限公司	一种4-叔丁氧羰基-2-环丙基吗啉的制备方法
SI3191487T1 (sl) *	2014-09-12	2019-12-31	Boehringer Ingelheim International Gmbh	Spirociklični inhibitorji katepsina C
AR102537A1 (es)	2014-11-05	2017-03-08	Flexus Biosciences Inc	Agentes inmunomoduladores
US11242319B2 (en)	2014-11-05	2022-02-08	Flexus Biosciences, Inc.	Immunoregulatory agents
UY36390A (es)	2014-11-05	2016-06-01	Flexus Biosciences Inc	Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
US10709692B2 (en) *	2015-12-04	2020-07-14	Denali Therapeutics Inc.	Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
US20220193048A1 (en)	2019-04-05	2022-06-23	Universite De Bretagne Occidentale	Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
WO2021147882A1 (zh) *	2020-01-21	2021-07-29	深圳信立泰药业股份有限公司	一种二苯并呋喃类衍生物组织蛋白酶k抑制剂及其制备方法和医药用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0621267A1 (en)	1993-04-07	1994-10-26	Shell Internationale Researchmaatschappij B.V.	Spiropiperidine derivatives and their use as fungicides
DE69730033T2 (de) *	1996-08-28	2005-07-21	The Procter & Gamble Company, Cincinnati	Spirocyclisch metalloprotease inhibitoren
EP1028942B1 (en)	1997-11-05	2010-09-01	Novartis AG	Dipeptide nitriles
JP2002539191A (ja)	1999-03-15	2002-11-19	アクシス・ファーマシューティカルズ・インコーポレイテッド	プロテアーゼ阻害剤としての新規化合物及び組成物
US6420364B1 (en) *	1999-09-13	2002-07-16	Boehringer Ingelheim Pharmaceuticals, Inc.	Compound useful as reversible inhibitors of cysteine proteases
ATE244235T1 (de)	1999-09-13	2003-07-15	Boehringer Ingelheim Pharma	Heterocyclische verbindungen als reversible inhibitoren von cysteinproteasen
GB0012240D0 (en)	2000-05-19	2000-07-12	Merck Sharp & Dohme	Therapeutic agents
JP4368581B2 (ja) *	2000-12-12	2009-11-18	シェーリングコーポレイション	Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としてのジアリールペプチド
CA2450167A1 (en) *	2001-06-12	2002-12-19	Elan Pharmaceuticals, Inc.	Macrocycles useful in the treatment of alzheimer's disease
DK1482924T3 (da)	2002-03-05	2008-09-29	Merck Frosst Canada Ltd	Cathepsin-cystein-protease-inhibotorer
CA2481369C (en) *	2002-04-11	2012-07-10	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
WO2003091202A1 (fr) *	2002-04-25	2003-11-06	Ono Pharmaceutical Co., Ltd.	Composes derives de dicetohydrazine et medicaments contenant ces composes comme ingredient actif
EP1569954A1 (en)	2002-12-05	2005-09-07	Axys Pharmaceuticals, Inc.	Cyanomethyl derivatives as cysteine protease inhibitors
EP1664090A2 (en) *	2003-08-26	2006-06-07	Schering Corporation	Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
EP1682524A1 (en)	2003-10-24	2006-07-26	Aventis Pharmaceuticals, Inc.	Novel keto-oxadiazole derivatives as cathepsin inhibitors

2007
- 2007-05-23 MY MYPI20084807A patent/MY156425A/en unknown
- 2007-05-23 CN CN201110216860.5A patent/CN102417480B/zh not_active Expired - Fee Related
- 2007-05-23 KR KR1020087029437A patent/KR101426317B1/ko not_active IP Right Cessation
- 2007-05-23 UA UAA200813750A patent/UA100669C2/ru unknown
- 2007-05-23 MX MX2008014800A patent/MX2008014800A/es active IP Right Grant
- 2007-05-23 CN CN200780020148XA patent/CN101460462B/zh not_active Expired - Fee Related
- 2007-05-23 CA CA2653662A patent/CA2653662C/en not_active Expired - Fee Related
- 2007-05-23 RU RU2008147128/04A patent/RU2478620C2/ru not_active IP Right Cessation
- 2007-05-23 SI SI200731045T patent/SI2032535T1/sl unknown
- 2007-05-23 EP EP07725450A patent/EP2032535B1/de active Active
- 2007-05-23 BR BRPI0711723-0A patent/BRPI0711723A2/pt not_active IP Right Cessation
- 2007-05-23 DK DK07725450.6T patent/DK2032535T3/da active
- 2007-05-23 MX MX2011009799A patent/MX341849B/es unknown
- 2007-05-23 JP JP2009512460A patent/JP5312320B2/ja not_active Expired - Fee Related
- 2007-05-23 ES ES07725450T patent/ES2392675T3/es active Active
- 2007-05-23 RS RS20120455A patent/RS52464B/en unknown
- 2007-05-23 PL PL07725450T patent/PL2032535T3/pl unknown
- 2007-05-23 NZ NZ573049A patent/NZ573049A/en not_active IP Right Cessation
- 2007-05-23 SG SG2011039849A patent/SG172661A1/en unknown
- 2007-05-23 UA UAA201209494A patent/UA107583C2/ru unknown
- 2007-05-23 EP EP12178418.5A patent/EP2520568B1/de not_active Not-in-force
- 2007-05-23 PT PT07725450T patent/PT2032535E/pt unknown
- 2007-05-23 AU AU2007267470A patent/AU2007267470B2/en not_active Ceased
- 2007-05-23 WO PCT/EP2007/004550 patent/WO2007137738A1/de active Application Filing
- 2007-05-30 JO JO2007207A patent/JO2741B1/en active
- 2007-05-30 DO DO2007000107A patent/DOP2007000107A/es unknown
- 2007-05-30 TW TW102106632A patent/TWI449706B/zh not_active IP Right Cessation
- 2007-05-30 PE PE2007000672A patent/PE20080104A1/es not_active Application Discontinuation
- 2007-05-30 TW TW096119211A patent/TWI396691B/zh not_active IP Right Cessation
- 2007-05-30 AR ARP070102324A patent/AR061599A1/es not_active Application Discontinuation
2008
- 2008-10-14 ZA ZA200808745A patent/ZA200808745B/xx unknown
- 2008-10-29 CR CR10409A patent/CR10409A/es unknown
- 2008-11-21 GT GT200800251A patent/GT200800251A/es unknown
- 2008-11-21 HN HN2008001723A patent/HN2008001723A/es unknown
- 2008-11-25 IL IL195519A patent/IL195519A/en active IP Right Grant
- 2008-11-25 US US12/277,880 patent/US8039480B2/en active Active
- 2008-11-28 TN TNP2008000494A patent/TNSN08494A1/en unknown
- 2008-11-28 EC EC2008008925A patent/ECSP088925A/es unknown
- 2008-11-28 MA MA31426A patent/MA30435B1/fr unknown
- 2008-12-08 NO NO20085107A patent/NO20085107L/no not_active Application Discontinuation
2009
- 2009-12-03 HK HK09111327.2A patent/HK1133255A1/xx not_active IP Right Cessation
- 2009-12-03 HK HK12109964.9A patent/HK1169119A1/zh not_active IP Right Cessation
2011
- 2011-09-29 US US13/248,366 patent/US8609681B2/en active Active
2012
- 2012-10-19 RU RU2012144638A patent/RU2621695C2/ru not_active IP Right Cessation
- 2012-10-23 HR HRP20120852TT patent/HRP20120852T1/hr unknown
- 2012-10-31 CY CY20121101039T patent/CY1113320T1/el unknown
2013
- 2013-07-01 JP JP2013137741A patent/JP5702834B2/ja not_active Expired - Fee Related
- 2013-11-22 US US14/087,854 patent/US20140073662A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AR061599A1 (es)	2008-09-10
KR101426317B1 (ko)	2014-08-06
US20090275523A1 (en)	2009-11-05
MA30435B1 (fr)	2009-05-04
NO20085107L (no)	2008-12-08
RU2008147128A (ru)	2010-06-10
RU2621695C2 (ru)	2017-06-07
UA100669C2 (ru)	2013-01-25
CN101460462A (zh)	2009-06-17
TWI449706B (zh)	2014-08-21
HK1169119A1 (zh)	2013-01-18
UA107583C2 (ru)	2015-01-26
US8039480B2 (en)	2011-10-18
CN101460462B (zh)	2013-07-31
HK1133255A1 (en)	2010-03-19
RU2012144638A (ru)	2014-04-27
RS52464B (en)	2013-02-28
MX2008014800A (es)	2008-12-02
CN102417480B (zh)	2015-08-26
US20140073662A1 (en)	2014-03-13
SG172661A1 (en)	2011-07-28
EP2032535A1 (de)	2009-03-11
SI2032535T1 (sl)	2012-12-31
EP2520568A1 (de)	2012-11-07
ES2392675T3 (es)	2012-12-12
US8609681B2 (en)	2013-12-17
GT200800251A (es)	2009-05-04
JP2009538843A (ja)	2009-11-12
KR20090015949A (ko)	2009-02-12
HN2008001723A (es)	2010-12-27
RU2478620C2 (ru)	2013-04-10
EP2032535B1 (de)	2012-08-01
TW200817418A (en)	2008-04-16
JP5702834B2 (ja)	2015-04-15
AU2007267470B2 (en)	2012-09-20
PE20080104A1 (es)	2008-03-25
AU2007267470A1 (en)	2007-12-06
JP2013209430A (ja)	2013-10-10
BRPI0711723A2 (pt)	2011-11-29
MX341849B (es)	2016-09-05
PT2032535E (pt)	2012-11-13
NZ573049A (en)	2010-08-27
DK2032535T3 (da)	2012-11-05
CN102417480A (zh)	2012-04-18
WO2007137738A1 (de)	2007-12-06
JO2741B1 (en)	2014-03-15
US20120015933A1 (en)	2012-01-19
IL195519A (en)	2012-12-31
CA2653662C (en)	2015-02-10
TW201345915A (zh)	2013-11-16
TNSN08494A1 (en)	2010-04-14
CR10409A (es)	2009-01-09
JP5312320B2 (ja)	2013-10-09
TWI396691B (zh)	2013-05-21
CY1113320T1 (el)	2016-04-13
DOP2007000107A (es)	2007-12-15
MY156425A (en)	2016-02-26
CA2653662A1 (en)	2007-12-06
ZA200808745B (en)	2009-11-25
HRP20120852T1 (hr)	2012-11-30
ECSP088925A (es)	2008-12-30
EP2520568B1 (de)	2015-09-09
IL195519A0 (en)	2009-09-01

Publication	Publication Date	Title
ZA200808745B (en)	2009-11-25	Spirocyclic nitriles as protease inhibitors
HK1148739A1 (en)	2011-09-16	Hcv protease inhibitors hcv
ZA200707650B (en)	2008-11-26	Azolylacylguanidines as ß-secretase inhibitors
EP2064177A4 (en)	2014-08-20	PROTEASE INHIBITORS
EP2313426A4 (en)	2012-01-18	NOVEL PROTEASE INHIBITORS
EP2358692A4 (en)	2012-06-27	CYSTEINE PROTEASE INHIBITORS
ZA201102179B (en)	2011-12-28	Protease inhibitors
HK1140480A1 (en)	2010-10-15	Cysteine protease inhibitors
GB0817425D0 (en)	2008-10-29	Protease inhibitors
GB0700369D0 (en)	2007-02-14	Protease inhibitors
GB0712176D0 (en)	2007-08-01	Protease inhibitors
GB0705213D0 (en)	2007-04-25	Protease inhibitors
GB0700378D0 (en)	2007-02-14	Protease inhibitors
GB0712543D0 (en)	2007-08-08	Protease inhibitors
GB0705212D0 (en)	2007-04-25	Protease inhibitors
GB0712544D0 (en)	2007-08-08	Protease inhibitors
AU2008904159A0 (en)	2008-09-04	Novel Protease Inhibitors
GB0712193D0 (en)	2007-08-01	Cysteine protease inhibitors
GB0724732D0 (en)	2008-01-30	Cysteine protease inhibitors
GB0712540D0 (en)	2007-08-08	Cysteine protease inhibitors
GB0712172D0 (en)	2007-08-01	Cysteine protease inhibitors
GB0703043D0 (en)	2007-03-28	Cysteine protease inhibitors
GB0712222D0 (en)	2007-08-01	Cysteine protease inhibitors
GB0712541D0 (en)	2007-08-08	Cysteine protease inhibitors
GB0707497D0 (en)	2007-05-23	Novel inhibitors